Comparison of lorazepam [7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy- 2H-1,4-benzodiazepin-2-one] occupancy of rat brain γ-aminobutyric acidA receptors measured using in vivo [3H]flumazenil (8-fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3- carboxylic acid ethyl ester) binding and [11C]flumazenil micro-positron emission

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 3, 2007, Pages 1030-1037

  Atack, John R ^a,d   Scott Stevens, Paul ^a   Beech, John S ^b   Fryer, Tim D ^b   Hughes, Jessica L ^b   Cleij, Marcel C ^b   Baron, Jean Claude ^b   Clark, John C ^b   Hargreaves, Richard J ^c   Aigbirhio, Franklin I ^b  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BRETAZENIL; FLUMAZENIL; FLUMAZENIL C 11; FLUMAZENIL H 3; LORAZEPAM; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN HOMOGENATE; CALCULATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSTIC EQUIPMENT AND SUPPLIES; RAT; SIMULATION;

ANIMALS; BINDING, COMPETITIVE; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUMAZENIL; INJECTIONS, INTRAVENOUS; LORAZEPAM; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A;

EID: 33847193862     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.114884     Document Type: Article

References (40)

1. Abadie P and Baron JC (1990) In Neurology and Psychiatry, PET and SPECT: Principles and Application (Diksic M and Reba RS eds) pp 357-379, CRC Press, Inc., Boca Raton, FL.
2. D values with positron emission tomography. Eur J Pharmacol 213:107-115.
3. A receptors as a target for the development of novel anxiolytics. Exp Opin Investig Drugs 14:601-618.
4. A receptors. Neuropsychopharmacology 20:255-262.
5. A receptors, is a non-sedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316:410-422.
6. Bell LE, Slattery JT, and Calkins DF (1985) Effect of halothane-oxygen anesthesia on the pharmacokinetics of diazepam and its metabolites in rats. J Pharmacol Exp Ther 233:94-99.
7. Brouillet E, Chavoix C, Bottlaender M, Khalili-Varasteh M, Hantraye P, Fournier D, Dodd RH, and Mazière M (1991) In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates. Brain Res 557:167-176.
8. Cheery SR and Chatziioannou AF (2005) Small animal PET systems, in Emission Tomography: The Fundamentals of PET and SPECT (Wernick MN and Aarsvold JN eds) pp 213-228, Elsevier, Amsterdam, The Netherlands.
9. 11C]flumazenil: captive solvent synthesis combined with purification by analytical sized columns. J Labelled Comp Radiopharm, in press.
10. 11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. Eur J Drug Metab Pharmacokinet 16:141-152.
11. Duffy RA, Varty GB, Morgan CA, and Lachowicz JE (2002) Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. J Pharmacol Exp Ther 301:536-542.
12. Fryer TD, Cleij MC, Aigbirhio FI, Beech JS, Barret O, Carpenter TA, Menon DK, Clark JC, and Baron JC (2002) Imaging benzodiazepine receptors in the rat brain using [11C]flumazenil and microPET. NeuroImage 16 (Suppl):S26.
13. A-benzodiazepine receptor binding by isoflurane. Anesthesiology 95:585-593.
14. Hansen TD, Warner DS, Todd MM, Baker MT, and Jensen NF (1991) The influence of inhalation anesthetics on in vivo and in vitro benzodiazepine receptor binding in the rat cerebral cortex. Anesthesiology 74:97-104.
15. A receptor complex. J Pharmacol Exp Ther 265:1392-1398.
16. Harris BD, Moody EJ, Basile AS, and Skolnick P (1994) Volatile anesthetics bidirectionally and stereospecifically modulate ligand binding to GABA receptors. Eur J Pharmacol 267:269-274.
17. Hume SP, Lammertsma AA, Myers R, Rajeswaran S, Bloomfield PM, Ashworth S, Fricker RA, Torres EM, Watson I, and Jones T (1996) The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J Neurosci Methods 67:103-112.
18. A receptor. J Neurosci 21:RC136(1-4).
19. Kinahan PE and Rogers JG (1990) Analytic 3D image reconstruction using all detected events. IEEE Trans Nucl Sci 36:964-968.
20. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735-744.
21. A receptors. Neuropharmacology 51:168-172.
22. 11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. Psychopharmacology 180:789-791.
23. Lister RG, Greenblatt DJ, Abernethy DR, and File SE (1984) Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the rat brain. Brain Res 290:183-186.
24. Lu Y, Dang H, Middleton B, Zhang Z, Washburn L, Stout DB, Campbell-Thompson M, Atkinson MA, Phelps M, Gambhir SS, et al. (2006) Noninvasive imaging of islet grafts using positron-emission tomography. Proc Natl Acad Sci USA 103:11294-11299.
25. 11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int J Appl Radiat Isot 35:973-976.
26. A and glycine receptors. Nature (Lond) 389:385-389.
27. 11C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. J Cereb Blood Flow Metab 8:304-313.
28. Phelps ME (2000) Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 97:9226-9233.
29. A receptors in humans. Anesth Analg 99:1420-1426.
30. 11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. Eur J Pharmacol, 110:247-251.
31. Savic I, Widen L, and Stone-Elander S (1991) Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet 337:133-137.
32. A receptor alpha-3 subunit. Brain Res 1032:30-35.
33. Strome EM, Cepeda IL, Sossi V, and Doudet DJ (2006) Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol Imaging Biol 8:292-299.
34. 123I]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain. Neuropharmacology 32:671-680.
35. Tai C, Chatziioannou A, Siegel S, Young J, Newport D, Goble RN, Nutt RE, and Cherry SR (2001) Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol 46:1845-1862.
36. 18F)-fluoromisonidazole and positron emission tomography: a pilot study. J Cereb Blood Flow Metab, in press.
37. Torres EM, Fricker RA, Hume SP, Myers R, Opacka-Juffry J, Ashworth S, Brooks DJ, and Dunnett SB (1995) Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. Neuroreport 6:2017-2021.
38. Wang J and Maurer L (2005) Positron emission tomography: applications in drug discovery and drug development. Curr Top Med Chem 5:1053-1075.
39. Wang X, Sarkar A, Cicchetti F, Yu M, Zhu A, Jokivarsi K, Saint-Pierre M, and Brownell AL (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci 231:57-66.
40. Yang Y, Tai YC, Siegel S, Newport DF, Bai B, Li Q, Leahy RM, and Cherry SR (2004) Optimization and performance evaluation of the microPET II scanner for in vivo small-animal imaging. Phys Med Biol 49:2527-2545.